MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 76 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.38 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,233,378 | +24.4% | 650,109 | +67.8% | 0.00% | 0.0% |
| Q2 2023 | $4,208,380 | +135.9% | 387,512 | +49.9% | 0.00% | – |
| Q1 2023 | $1,783,705 | +5.8% | 258,508 | -39.0% | 0.00% | – |
| Q4 2022 | $1,685,443 | -13.1% | 423,478 | +45.1% | 0.00% | – |
| Q3 2022 | $1,939,000 | +42.2% | 291,753 | +3.5% | 0.00% | – |
| Q2 2022 | $1,364,000 | -6.4% | 281,865 | +80.8% | 0.00% | – |
| Q1 2022 | $1,458,000 | -69.6% | 155,925 | -61.4% | 0.00% | -100.0% |
| Q4 2021 | $4,801,000 | +53.7% | 404,140 | +47.2% | 0.00% | – |
| Q3 2021 | $3,123,000 | -60.4% | 274,552 | -37.5% | 0.00% | -100.0% |
| Q2 2021 | $7,887,000 | +64.7% | 439,615 | +42.1% | 0.00% | +100.0% |
| Q1 2021 | $4,789,000 | +30.7% | 309,391 | +3.0% | 0.00% | 0.0% |
| Q4 2020 | $3,665,000 | +448.7% | 300,425 | +477.4% | 0.00% | – |
| Q3 2020 | $668,000 | – | 52,028 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,629,622 | $33,936,000 | 7.88% |
| VR Adviser, LLC | 3,156,803 | $29,516,000 | 4.78% |
| Bleichroeder LP | 1,322,463 | $12,365,000 | 2.19% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $13,380,000 | 1.30% |
| 683 Capital Management, LLC | 1,932,829 | $18,072,000 | 0.97% |
| Granite Point Capital Management, L.P. | 472,056 | $4,414,000 | 0.92% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,766,000 | $25,862,000 | 0.79% |
| Avoro Capital Advisors LLC | 3,150,000 | $29,453,000 | 0.54% |
| Artal Group S.A. | 1,000,000 | $9,350,000 | 0.39% |
| Stonepine Capital Management, LLC | 56,747 | $531,000 | 0.22% |